Concerns have emerged about rare cases of blood clots linked to the Johnson & Johnson and AstraZeneca vaccines, but scientists say they have found a way to solve the problem.

A team of German scientists believes the Covid-19 vaccines developed by Oxford-AstraZeneca and Johnson & Johnson (J&J) can be redesigned to avoid the rare, but potentially harmful, blood clots that have been reported in vaccinated people.
The J&J and the AstraZeneca vaccines used a similar technology, known as adenoviral vectors, leading some experts to speculate there might be a link between this vaccine platform and the blood clotting condition, Dr Kylie Quinn said in an article in The Conversation.
The condition is known as vaccine-induced immune thrombotic thrombocytopenia (VITT).